Home
Stock Market News
Market Sentiment
Trending Industries
Blogs
Contact us
Outlook Therapeutics Trial of Eye Disease Treatment Misses Key Endpoint
Outlook Therapeutics plans to resubmit a biologics license application for ONS-5010, an ophthalmic formulation of bevacizumab, after a trial missed a key target.